Thus, we sought to address this preclinical gap by quantifying ASM potency and tolerability in PSEN2-knockout (KO) mice to determine whether mice with an AD-related genotype and a breeding strategy suitable for efficient high-throughput ASM discovery could reflect a useful preclinical ASM screening platform for seizures in individuals with AD. Here, PSEN2 is linked to Alzheimer disease.